H.Z. KE ET AL: "BONE ANABOLISM ACHEIVED BY REDUCING SCLEROSTIN BIOAVAILABILITY WITH AN ANTI-sclerostin antibody", 36TH INTERNATIONAL SUN VALLEY WORKSHOP ON SKELETAL TISSUE BIOLOGY, 30 July 2006 (2006-07-30), page 02.08.2006, XP002469781, (B1)

HOLDSWORTH GILL ET AL: "Characterization of the Interaction of Sclerostin with the Low Density Lipoprotein Receptor-related Protein (LRP) Family of Wnt Co-receptors", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 287, no. 32, August 2012 (2012-08), pages 26464-26477, ISSN: 0021-9258(print) (B1)

I. KYOJI: "Physiological function of osteocytes", CLINICAL CALCIUM, vol. 17, no. 10, 1 October 2007 (2007-10-01), pages 1554-1558, XP008088787, (B1)

LEWIECKI E MICHAEL: "Sclerostin monoclonal antibody therapy with AMG 785: a potential treatment for osteoporosis", EXPERT OPINION ON BIOLOGICAL THERAPY, INFORMA HEALTHCARE, UK, vol. 11, no. 1, 1 January 2011 (2011-01-01), pages 117-127, XP009160541, ISSN: 1744-7682, DOI: 10.1517/14712598.2011.540565 (B1)

LINTERN KATHERINE B ET AL: "Characterization of wise protein and its molecular mechanism to interact with both Wnt and BMP signals.", THE JOURNAL OF BIOLOGICAL CHEMISTRY 21 AUG 2009, vol. 284, no. 34, 21 August 2009 (2009-08-21), pages 23159-23168, ISSN: 1083-351X (B1)

WO-A-2006/119062 (B1)

VAN BEZOOIJEN R L ET AL: "BONE MORPHOGENETIC PROTEINS AND THEIR ANTAGONISTS: THE SCLEROSTIN PARADIGM", JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, KURTIS, MILAN, IT, vol. 28, no. 8, 2005, pages 15-17, XP008078167, ISSN: 0391-4097 (B1)

VEVERKA VACLAV ET AL: "Characterization of the structural features and interactions of sclerostin: molecular insight into a key regulator of Wnt-mediated bone formation", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 284, no. 16, 17 April 2009 (2009-04-17), pages 10890-10900, XP002594504, ISSN: 0021-9258, DOI: 10.1074/JBC.M807994200 [retrieved on 2009-02-10] (B1)

WARMINGTON K ET AL: "SCIEROSTIN ANTAGONISM IN ADULT RODENTS, VIA MONOCLONAL ANTIBODY MEDIATED BLOCKADE, INCREASES BONE MINERAL DENSITY AND IMPLICATES SCLEROSTIN AS A KEY REGULATOR OF BONE MASS DURING ADULTHOOD", JOURNAL OF BONE AND MINERAL RESEARCH, NEW YORK, NY, US, vol. 19, 5 October 2004 (2004-10-05), pages S56-S57,ABSTRA, XP009072609, ISSN: 0884-0431 (B1)

WARMINGTON K ET AL: "SCLEROSTIN MONOCLONAL ANTIBODY TREATMENT OF OSTEOPOROTIC RATS COMPLETELY REVERSES ONE YEAR OF OVARIECTOMY-INDUCED SYSTEMIC BONE LOSS", JOURNAL OF BONE AND MINERAL RESEARCH, NEW YORK, NY, US, vol. 20, no. 9, 25 September 2005 (2005-09-25), pages S22-PRES1082, XP008078248, ISSN: 0884-0431 (B1)

OMINSKY M S ET AL: "SCLEROSTIN MONOCLONAL ANTIBODY TREATMENT INCREASES BONE STRENGTH IN AGED OSTEOPENIC OVARIECTOMIZED RATS", JOURNAL OF BONE AND MINERAL RESEARCH, NEW YORK, NY, US, vol. 21, no. 1, 18 September 2006 (2006-09-18), page S44PRES1161, XP008078247, ISSN: 0884-0431 (B1)